Carregant...
CAR T-cell therapy: is it prime time in myeloma?
Chimeric antigen receptor (CAR) T cells have shown promising activity in hematological malignancies and are being studied for the treatment of multiple myeloma, as well. B-cell maturation antigen, which is widely and almost exclusively expressed on plasma cells and B cells, is a promising target. Ot...
Guardat en:
| Publicat a: | Hematology Am Soc Hematol Educ Program |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
American Society of Hematology
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6913444/ https://ncbi.nlm.nih.gov/pubmed/31808895 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/hematology.2019000370 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|